回生胶囊对二甲基苯蒽诱导的骨髓增生异常综合征模型大鼠的影响
|
摘要
目的:探讨回生胶囊对二甲基苯蒽(DMBA)诱导的骨髓增生异常综合征(myelodysplastic syndrome,MDS)大鼠模型的影响。方法:将60只SD大鼠随机分为正常组、模型组、环孢素组、回生胶囊高剂量组、低剂量组,每组12只。除正常组外,其他大鼠均采用化学诱变剂二甲基苯蒽建立MDS模型,于实验第14天各组开始给药,连续30 d。观察各组大鼠一般情况,病态造血,全自动血细胞分析仪检测外周血细胞,流式细胞仪检测外周血中CD3~+、CD4~+、CD8~+、CD4~+/CD8~+水平,ELISA法检测外周血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平。结果:模型组外周血和骨髓均见不同程度的病态造血,外周血中白细胞、红细胞、血红蛋白、血小板、CD3~+、CD4~+、CD4~+/CD8~+水平显著降低(P<0.01),TNF-α、IL-6水平显著升高(P<0.01);与模型组相比,各给药组均可不同程度地改善病态造血,外周血象、T淋巴细胞水平显著升高(P<0.01或P<0.05),TNF-α、IL-6水平显著降低(P<0.01或P<0.05)。结论:回生胶囊可通过改善MDS模型大鼠病态造血,升高外周血象、调节外周血T淋巴细胞水平,减少TNF-α、IL-6的释放,发挥抗肿瘤作用,且药物剂量与疗效呈正相关。
Objective: To investigate the effects of Huisheng capsule on rats with myelodysplastic syndrome(MDS)induced by dimethyl benzanthracene(DMBA).Methods:Sixty rats were randomly divided into normal group,model group,cyclosporine group,high-dose group of Huisheng capsule and low-dose group of Huisheng capsule,with 12 rats in each group.Except for the normal group,other rats were establish the MDS model by the chemical mutagen DMBA,the rats of each group were treated with different drugs on the 14 th day and treated continuously for 30 days.The general condition of rats in each group was observed.The pathological hematopoiesis was observed by microscopes. The peripheral blood was detected by automatic blood cell analyzer. The levels of CD3~+,CD4~+,CD8~+ and CD4~+/CD8~+ in peripheral blood were detected by flow cytometry. TNF-α and IL-6 were detected by ELISA.Results:Compared with the normal group,the model group showed three types of pathological hematopoiesis. The levels of white blood cells,red blood cells,hemoglobin,platelets,CD3~+,CD4~+,CD4~+/CD8~+ in peripheral blood were significantly decreased(P<0.01),TNF-α and IL-6 levels significantly increased(P <0.01). Compared with the model group,each treatment group could improve pathological hematopoiesis in different degrees,significantly increase peripheral blood and T lymphocyte levels(P <0.01 or P <0.05),and significantly reduce TNF-α and IL-6 levels(P <0.01 or P <0.05). Conclusion:Huisheng capsule could exert anti-tumor effect by improving the bone marrow pathological hematopoiesis,increase the peripheral blood picture,regulate the ratio of peripheral blood T lymphocytes,reduce the release of TNF-α and IL-6. And the drug dose was positively correlated with the efficacy.
Objective: To investigate the effects of Huisheng capsule on rats with myelodysplastic syndrome(MDS)induced by dimethyl benzanthracene(DMBA).Methods:Sixty rats were randomly divided into normal group,model group,cyclosporine group,high-dose group of Huisheng capsule and low-dose group of Huisheng capsule,with 12 rats in each group.Except for the normal group,other rats were establish the MDS model by the chemical mutagen DMBA,the rats of each group were treated with different drugs on the 14 th day and treated continuously for 30 days.The general condition of rats in each group was observed.The pathological hematopoiesis was observed by microscopes. The peripheral blood was detected by automatic blood cell analyzer. The levels of CD3~+,CD4~+,CD8~+ and CD4~+/CD8~+ in peripheral blood were detected by flow cytometry. TNF-α and IL-6 were detected by ELISA.Results:Compared with the normal group,the model group showed three types of pathological hematopoiesis. The levels of white blood cells,red blood cells,hemoglobin,platelets,CD3~+,CD4~+,CD4~+/CD8~+ in peripheral blood were significantly decreased(P<0.01),TNF-α and IL-6 levels significantly increased(P <0.01). Compared with the model group,each treatment group could improve pathological hematopoiesis in different degrees,significantly increase peripheral blood and T lymphocyte levels(P <0.01 or P <0.05),and significantly reduce TNF-α and IL-6 levels(P <0.01 or P <0.05). Conclusion:Huisheng capsule could exert anti-tumor effect by improving the bone marrow pathological hematopoiesis,increase the peripheral blood picture,regulate the ratio of peripheral blood T lymphocytes,reduce the release of TNF-α and IL-6. And the drug dose was positively correlated with the efficacy.
引文
[1]Platzbecker U,Santini V,Mufti G J,et al.Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes(MDS):consensus statements and report from an expert workshop[J].Leukemia Research,2012,36(3):264-270.
[2]夏小军,段赟,崔杰,等.回生胶囊配合小剂量化疗治疗老年急性髓细胞性白血病22例临床观察[J].甘肃医药,2016,35(6):431-432.
[3]郭炳涛.回生胶囊治疗低危骨髓增生异常综合征的临床观察[D].兰州:甘肃中医药大学,2017.
[4]王猛,张钧寿,周建平.注射用辅料泊洛沙姆188[J].药学与临床研究,2007,15(1):10-13.
[5]冯宝章,赵堂富,王素钦,等.骨髓增生异常综合征大鼠模型的建立及其鉴定[J].中国实验血液学杂志,1996(3):309-313.
[6]陈信义,麻柔,李冬云.规范常见血液病中医病名建议[J].中国中西医结合杂志,2009,29(11):1040-1041.
[7]殷建峰.回生胶囊毒理学、药效学实验研究[J].西部中医药,2016,29(5):26-31.
[8]彭澄,李俊勋,欧阳涓.病态造血形态学特征与血液系统疾病相关性研究进展[J].宁波大学学报(理工版),2014(4):108-114.
[9]严健,原永明,张舒,等.CD3+、CD4+、CD8+T淋巴细胞亚群在肿瘤患者外周血中检测的临床意义[J].检验医学,2013,28(10):901-903.
[10]Sawanobori M,Yamaguchi S,Hasegawa M,et al.Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes[J].Leukemia Research,2003,27(7):583.
[11]沙琨.骨髓增生异常综合征骨髓细胞凋亡与TNF-α关系的探讨[J].中国实用医药,2014(23):91-92.
[12]刘徽,朱波,林治华.IL-6信号通路与肿瘤[J].细胞与分子免疫学志,2011,27(3):353-355.
[2]夏小军,段赟,崔杰,等.回生胶囊配合小剂量化疗治疗老年急性髓细胞性白血病22例临床观察[J].甘肃医药,2016,35(6):431-432.
[3]郭炳涛.回生胶囊治疗低危骨髓增生异常综合征的临床观察[D].兰州:甘肃中医药大学,2017.
[4]王猛,张钧寿,周建平.注射用辅料泊洛沙姆188[J].药学与临床研究,2007,15(1):10-13.
[5]冯宝章,赵堂富,王素钦,等.骨髓增生异常综合征大鼠模型的建立及其鉴定[J].中国实验血液学杂志,1996(3):309-313.
[6]陈信义,麻柔,李冬云.规范常见血液病中医病名建议[J].中国中西医结合杂志,2009,29(11):1040-1041.
[7]殷建峰.回生胶囊毒理学、药效学实验研究[J].西部中医药,2016,29(5):26-31.
[8]彭澄,李俊勋,欧阳涓.病态造血形态学特征与血液系统疾病相关性研究进展[J].宁波大学学报(理工版),2014(4):108-114.
[9]严健,原永明,张舒,等.CD3+、CD4+、CD8+T淋巴细胞亚群在肿瘤患者外周血中检测的临床意义[J].检验医学,2013,28(10):901-903.
[10]Sawanobori M,Yamaguchi S,Hasegawa M,et al.Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes[J].Leukemia Research,2003,27(7):583.
[11]沙琨.骨髓增生异常综合征骨髓细胞凋亡与TNF-α关系的探讨[J].中国实用医药,2014(23):91-92.
[12]刘徽,朱波,林治华.IL-6信号通路与肿瘤[J].细胞与分子免疫学志,2011,27(3):353-355.